1. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial.
- Author
-
Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Rojas M, Mora AL, Rocha CL, Alvarado F, and Falla JC
- Subjects
- Adolescent, Adult, Amino Acid Sequence, Animals, Blood Pressure, Blotting, Western, Child, Child, Preschool, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G biosynthesis, Infant, Male, Molecular Sequence Data, Protozoan Proteins adverse effects, Protozoan Proteins chemistry, Protozoan Vaccines adverse effects, Protozoan Vaccines chemistry, Vaccination adverse effects, Antibodies, Protozoan biosynthesis, Malaria, Falciparum prevention & control, Plasmodium falciparum immunology, Protozoan Proteins immunology, Protozoan Vaccines immunology, Recombinant Proteins
- Abstract
In the first field trial with synthetic malaria vaccine SPf66 in a large population naturally exposed to malaria, 9957 persons greater than 1 year old and residing on the Colombian Pacific coast received three doses of the vaccine. To evaluate vaccine safety, clinical observations were made 30 min and 48 h after each immunization. There were no adverse reactions in 95.7% of cases. In the 4.3% of cases with adverse reactions, local induration and erythema were the most frequent. In a randomly selected group of vaccinees, anti-SPf66 antibody titers were measured after the third dose: 93% of the vaccinees raised antibodies to SPf66. Among these, 55% had titers greater than 1:1600. These results demonstrate the safety and immunogenicity of the SPf66 vaccine in a large field trial.
- Published
- 1992
- Full Text
- View/download PDF